Genetic alterations in Sezary syndrome

References

• Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet 2008;371:945–957.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105: 3768–3785.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. 4th edLyonIARC Press2008.
   Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009;114:4337–4353.
   PubMed Web of Science ®Google Scholar
• Crossen PE, Mellor JE, Finley AG, Ravich RB, Vincent PC, Gunz FW. The Sézary syndrome: cytogenetic studies and identification of the Sézary cell as an abnormal lymphocyte. Am J Med 1971;50:24–34.
   PubMed Web of Science ®Google Scholar
• Bosman FT, van Vloten WA. Sézary's syndrome: a cytogenetic, cytophotometric and autoradiographic study. J Pathol 1976;118:49–57.
   PubMed Web of Science ®Google Scholar
• Whang-Peng J, Lutzner M, Edelson R, Knutsen T. Cytogenetic studies and clinical implications in patients with Sézary syndrome. Cancer 1976;382:861–867.
   Web of Science ®Google Scholar
• Goh KO, Reddy MM, Joishy SK. Chromosomes and B and T cells in mycosis fungoides. Am J Med Sci 1978;276:197–204.
   PubMed Web of Science ®Google Scholar
• Whang-Peng J, Bunn P, Knutsen T, et al. Cytogenetic abnormalities in patients with cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:575–580.
   PubMedGoogle Scholar
• Shah-Reddy I, Mayeda K, Mirchandani I, Koppitch FC. Sézary syndrome with a 14:14 (q12:q31) translocation. Cancer 1982;49:75–79.
   PubMed Web of Science ®Google Scholar
• Whang-Peng J, Bunn PA Jr, Knutsen T, Matthews MJ, Schechter G, Minna JD. Clinical implications of cytogenetic studies in cutaneous T-cell lymphoma (CTCL). Cancer 1982;50:1539–1553.
   PubMed Web of Science ®Google Scholar
• Johnson GA, Dewald GW, Strand WR, Winkelmann RK. Chromosome studies in 17 patients with the Sézary syndrome. Cancer 1985;55:2426–2433.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Stolzmann WM, Neumann E. Cytogenetic findings in a case of Sézary syndrome. Cancer Genet Cytogenet 1985;16:117–121.
   PubMed Web of Science ®Google Scholar
• Berger R, Bernheim A. Cytogenetic studies of Sézary cells. Cancer Genet Cytogenet 1987;27:79–87.
   PubMed Web of Science ®Google Scholar
• D'Alessandro E, Paterlini P, Lo Re ML, et al. Cytogenetic follow-up in a case of Sézary syndrome. Cancer Genet Cytogenet 1990;452:231–236.
   Web of Science ®Google Scholar
• D'Alessandro E, De Pasquale A, Ligas C, et al. Cytogenetic findings in terminal large cell transformation in a case of Sézary syndrome. Cancer Genet Cytogenet 1992;58:100–104.
   PubMed Web of Science ®Google Scholar
• Solé F, Woessner S, Vallespi T, et al. Cytogenetic studies in five patients with Sézary syndrome. Cancer Genet Cytogenet 1994;75:130–132.
   PubMed Web of Science ®Google Scholar
• Limon J, Nedoszytko B, Brozek I, et al. Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome. Cancer Genet Cytogenet 1995;83:75–81.
   PubMed Web of Science ®Google Scholar
• Thangavelu M, Finn WG, Yelavarthi KK, et al. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood 1997;89:3371–3377.
   PubMed Web of Science ®Google Scholar
• Mohr B, Illmer T, Oelschlägel U, et al. Complex cytogenetic and immunophenotypic aberrations in a patient with Sezary syndrome. Cancer Genet Cytogenet 1996;90:33–36.
   PubMed Web of Science ®Google Scholar
• Karenko L, Hyytinen E, Sarna S, Ranki A. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol 1997; 108:22–29.
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle V, Maljaie SH, Matutes E, Hedges M, Yuille M, Catovsky D. Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: a cytogenetic analysis with in situ hybridization. Br J Haematol 1997;96: 724–732.
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle V, Hamoudi R, Matutes E, et al. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. Br J Haematol 2000;110:180–187.
   PubMed Web of Science ®Google Scholar
• Espinet B, Salido M, Pujol RM, et al. Genetic characterization of Sézary's syndrome by conventional cytogenetics and cross-species color banding fluorescent in situ hybridization. Haematologica 2004;89:165–173.
   PubMed Web of Science ®Google Scholar
• Batista DA, Vonderheid EC, Hawkins A, et al. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities. Genes Chromosomes Cancer 2006;45:383–391.
   PubMed Web of Science ®Google Scholar
• Karenko L, Hahtola S, Päivinen S, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res 2005;65: 8101–8110.
   PubMed Web of Science ®Google Scholar
• Vermeer MH, van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res 2008;68:2689–2698.
   PubMed Web of Science ®Google Scholar
• Karenko L, Kähkönen M, Hyytinen E, Lindlof M, Ranki A. Notable losses at specific regions of chromosomes 10q and 13q in the Sezary syndrome detected by comparative genomic hybridization. J Invest Dermatol 1999;112:392–395.
   PubMed Web of Science ®Google Scholar
• Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas:identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol 2002;147:464–475.
   PubMed Web of Science ®Google Scholar
• Mao X, Lillington DM, Czepulkowski B, Russell-Jones R, Young BD, Whittaker S. Molecular cytogenetic characterization of Sézary syndrome. Genes Chromosomes Cancer 2003;36:250–260.
   PubMed Web of Science ®Google Scholar
• Barba G, Matteucci C, Girolomoni G, et al. Comparative genomic hybridization identifies 17q11.2 approximately q12 duplication as an early event in cutaneous T-cell lymphomas. Cancer Genet Cytogenet 2008;184:48–51.
   PubMed Web of Science ®Google Scholar
• Caprini E, Cristofoletti C, Arcelli D, et al. Identification of key regions and genes important in the pathogenesis of Sezary syndrome by combining genomic and expression microarrays. Cancer Res 2009;69:8438–8446.
   PubMedGoogle Scholar
• Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol 2010;130:1707–1718.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. J Invest Dermatol 2001;117:663–670.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Woolford AJ, Calonje E, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome. J Invest Dermatol 2002;118:493–499.
   PubMed Web of Science ®Google Scholar
• Wain EM, Mitchell TJ, Russell-Jones R, Whittaker SJ. Fine mapping of chromosome 10q deletions in mycosis fungoides and sezary syndrome:identification of two discrete regions of deletion at 10q23.33-24.1 and 10q24.33-25.1. Genes Chromosomes Cancer 2005;42:184–192.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 2000;95:2937–2942.
   PubMed Web of Science ®Google Scholar
• Logarinho E, Resende T, Torres C, Bousbaa H. The human spindle assembly checkpoint protein Bub3 is required for the establishment of efficient kinetochore-microtubule attachments. Mol Biol Cell 2008;19:1798–1813.
   PubMed Web of Science ®Google Scholar
• van Doorn R, Dijkman R, Vermeer MH, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis. Cancer Res 2004;64:5578–5586.
   PubMed Web of Science ®Google Scholar
• Maestro R, Dei Tos AP, Hamamori Y, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13: 2207–2217.
   PubMed Web of Science ®Google Scholar
• Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002;3:475–86.
   PubMed Web of Science ®Google Scholar
• Henriksson M, Lüscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996;68:109–182.
   PubMed Web of Science ®Google Scholar
• Soucek L, Evan G. Myc–Is this the oncogene from hell? Cancer Cell 2002;1:406–8.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996;93:9148–9153.
   PubMed Web of Science ®Google Scholar
• Showe LC, Fox FE, Williams D, Au K, Niu Z, Rook AH. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J Immunol 1999;163:4073–4079.
   PubMed Web of Science ®Google Scholar
• Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001;15:787–793.
   PubMed Web of Science ®Google Scholar
• Mitchell TJ, Whittaker SJ, John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res 2003;63:9048–9054.
   PubMed Web of Science ®Google Scholar
• van Kester MS, Out-Luiting JJ, von dem Borne PA, Willemze R, Tensen CP, Vermeer MH. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sézary cells. J Invest Dermatol 2008;128:1691–1695.
   PubMed Web of Science ®Google Scholar
• Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003;197:1477–1488.
   PubMed Web of Science ®Google Scholar
• Utikal J, Poenitz N, Gratchev A, et al. Additional Her 2/neu gene copies in patients with Sézary syndrome. Leuk Res 2006;30:755–760.
   PubMed Web of Science ®Google Scholar
• Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003;101:1513–1519.
   PubMed Web of Science ®Google Scholar
• Dereure O, Portales P, Clot J, Guilhou JJ. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol 2000;143:1205–1210.
   PubMed Web of Science ®Google Scholar
• Fischer TC, Gellrich S, Muche JM, et al. Genomic aberrations and survival in cutaneous T cell lymphomas. Invest Dermatol 2004;122:579–586.
   PubMed Web of Science ®Google Scholar
• Karenko L, Sarna S, Kähkönen M, Ranki A. Chromosomal abnormalities in relation to clinical disease in patients with cutaneous T-cell lymphoma:a 5-year follow-up study. Br J Dermatol 2003;148:55–64.
   PubMed Web of Science ®Google Scholar
• Marty M, Prochazkova M, Laharanne E, et al. Primary cutaneous T-cell lymphomas do not show specific NAV3 gene deletion or translocation. J Invest Dermatol 2008;128:2458–2466.
   PubMed Web of Science ®Google Scholar
• van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009;113:127–136.
   PubMedGoogle Scholar
• Prochazkova M, Chevret E, Mainhaguiet G, et al. Common chromosomal abnormalities in mycosis fungoides transformation. Genes Chromosomes Cancer 2007;46:828–838.
   PubMed Web of Science ®Google Scholar
• Booken N, Gratchev A, Utikal J, et al. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008;22:393–399.
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010;116:767–771.
   PubMed Web of Science ®Google Scholar
• Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043–1048.
   PubMed Web of Science ®Google Scholar